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Abstract 34 
Background 35 
Space Agencies are planning human missions beyond Low Earth Orbit.  Consideration of how 36 
physiological system adaptation with microgravity (µG) will be managed during these mission 37 
scenarios is required.  Exercise countermeasures (CM) could be used more sparingly to 38 
decrease limited resource costs, including periods of no exercise. This study provides a 39 
complete overview of the current evidence, making recommendations on the length of time 40 
humans exposed to simulated µG might safely perform no exercise considering muscles only. 41 
 42 
Methods 43 
Electronic databases were searched for astronaut or space simulation bed rest studies, as the 44 
most valid terrestrial simulation, from start of records to July 2017.  Studies were assessed with 45 
the Quality in Prognostic Studies and bed rest analogue studies assessed for transferability to 46 
astronauts using the Aerospace Medicine Systematic Review Group Tool for Assessing Bed 47 
Rest Methods.  Effect sizes, based on no CM groups, were used to assess muscle outcomes 48 
over time. Outcomes included were contractile work capacity, muscle cross sectional area, 49 
muscle activity, muscle thickness, muscle volume, maximal voluntary contraction force during 50 
one repetition maximum, peak power, performance based outcomes, power and 51 
torque/strength. 52 
 53 
Results 54 
75 bed rest µG simulation studies were included, many with high risk of confounding factors 55 
and participation bias.  Most muscle outcomes deteriorated over time with no countermeasures.  56 
Moderate effects were apparent by 7-15 days and large by 28-56 days.  Moderate effects (>0.6) 57 
became apparent in the following order, power and MVC during one repetition maximum (7 58 
days), followed by volume, cross sectional area, torques and strengths, contractile work 59 
capacity, thickness and endurance (14 days), then muscle activity (15 days).  Large effects 60 
(>1.2) became apparent in the following order, volume, cross sectional area (28 days) torques 61 
and strengths, thickness (35 days) and peak power (56 days).    62 
 63 
Conclusions 64 
Moderate effects on a range of muscle parameters may occur within 7-14 days of unloading, 65 
with large effects within 35 days. Combined with muscle performance requirements for 66 
mission tasks, these data, may support the design of CM programmes to maximise efficiency 67 
without compromising crew safety and mission success when incorporated with data from 68 
additional physiological systems that also need consideration. 69 
  70 
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1. Introduction 71 
1.1. Rationale 72 
Space Agencies are planning to transition from International Space Station (ISS) missions to 73 
Lunar missions including a crewed base from which to test and develop hardware and 74 
procedures required for the longer term goal of human Mars missions (Foing 2016).  It is well 75 
documented that exposure to microgravity (µG) during spaceflight causes adaptation in 76 
response to gravitational unloading, especially in the musculoskeletal, cardiovascular and 77 
neuro-vestibular systems (Buckey 2006, Baker 2008).  The risks to mission success due to 78 
potential injury or reduced function due to periods of unmanaged adaptation before arriving 79 
at a remote location such as Moon or Mars, where medical teams may not be present on 80 
landing, need to be addressed (Gernand 2004).  Bed rest is often used as a controlled Earth-81 
based environment for simulating the effects of spaceflight on humans to enable more cost-82 
effective, higher quality and safer research into effects and medical management of 83 
adaptation (Pavy-Le Traon, Heer et al. 2007).  While bed rest fails to remove a Gx (chest-to-84 
back) loading vector, such studies are considered the most valid simulation method for many 85 
physiological systems (Adams, Caiozzo et al. 2003, Pavy-Le Traon, Heer et al. 2007), except 86 
for weight bearing, tissue fluid redistributions and skin surface areas of compression 87 
(Hargens and Vico 2016), and when conducted rigorously are likely to generate results 88 
transferable to astronauts (Higgins and Green 2011, Winnard and Nasser 2017).   89 
Based on bed rest research and previous spaceflight experience, the ISS provides astronauts 90 
with 2.5 hours per day for exercise (including setup, stowage and hygiene) using a treadmill, 91 
cycle ergometer and resistance exercise device designed and adapted for µG (Trappe, Costill 92 
et al. 2009, Loehr, Lee et al. 2011).  Several years of refining ISS exercise countermeasures 93 
(CM) has led to astronauts completing 6-month missions with, on average, little to no change 94 
in bone mass or cardiovascular capacity, although the efficacy seems to vary widely between 95 
individuals (Moore., Downs et al. 2014, English, Lee et al. 2015, Sibonga, Spector et al. 96 
2015), while muscle adaptation appears to have become progressively smaller as exercise 97 
devices and prescriptions have improved (Smith, Heer et al. 2012, Moore., Downs et al. 98 
2014, Ploutz-Snyder, Ryder et al. 2015).  However, the exercise devices currently aboard ISS 99 
will almost certainly be too large and too numerous for, and the exercise prescriptions place 100 
too great a demand on the consumables and environmental management systems available 101 
on, the vehicles and habitats currently planned for future exploration missions.  For this 102 
reason, space agencies have started designing smaller, low energy and low vibration exercise 103 
devices (Brusco 2016).  However, decisions will need to be made regarding choice and/or 104 
development of an effective exercise CM programme to manage physiological adaptation that 105 
will occur during exploration missions.  Considerations may include reducing the frequency 106 
of exercise as currently performed on ISS and potentially having longer periods of not 107 
performing any exercise.  The duration of any such no exercise periods needs to be evidence 108 
based to balance any increase physiological risks to crew against gains in spacecraft and 109 
consumables impact.  110 
1.2. Objectives 111 
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The objectives of this review were to provide a complete summary of and synthesise the 112 
current space-related physiological evidence base and to inform decision making processes 113 
around muscle performance requirements, regarding operational CM, for exploration human 114 
space missions.  Where data is lacking for any outcomes this will be highlighted as a gap or 115 
limited area of the current evidence base and used to provide a gap analysis commentary 116 
useful for future research priority setting.  The aim is to aid space agencies in designing CM 117 
programmes, provide a complete summary of what muscle groups and outcomes have been 118 
assessed in the current evidence and highlight areas of minimal data or research gaps to guide 119 
future relevant research in this area.  The NASA Risk Table for the Human Research Project 120 
highlights potential risks relating to spaceflight and shows the large scope of potential 121 
physiological systems that require reviewing to cover all elements of crew health and 122 
performance (NASA 2019).  As the scope is too large for a single review, it is suggested that 123 
the various systems be reviewed individually.  Once a series of reviews has been complete a 124 
position statement summarising across each system can provide a holistic overview.  125 
Therefore,this specific review investigated the rate at which muscle parameters change during 126 
simulated µG exposure, when no countermeasures are taken, to inform operational decisions 127 
regarding the possibility of using exercise CM programmes more sparingly for exploration 128 
missions, including the implementation of exercise ‘holidays; (i.e. a period of time within the 129 
mission when no exercise CM are employed).  Conclusions of this review alone must be 130 
treated in a muscle context and need considering alongside other relevant health and 131 
performance components. 132 
1.3. Research question 133 
At what time point do people exposed to simulated µG while not performing CM reach a 134 
moderate or large effect on muscle health outcomes?   135 
2. Methods 136 
2.1. Study design 137 
The Cochrane Collaboration Guidebook (Higgins and Green 2011) and preferred reporting 138 
items for systematic reviews and meta-analyses (PRISMA) were adhered to (Moher, Liberati 139 
et al. 2009).  No external funding or research grants were received for this work. 140 
2.1.1. Participants 141 
The following inclusion criteria were employed.  The target population was astronauts, 142 
however, as astronauts have taken part in space agency recommended exercise programmes 143 
to date, there was no inactive data available from this population.  Therefore, healthy 144 
terrestrial adults, with no gender restrictions, taking part in µG analogue bed rest studies, 145 
were included. Bed rest studies were the only terrestrial model included as they are 146 
considered the most valid ground based model for simulating human spaceflight for periods 147 
beyond a few minutes(Adams, Caiozzo et al. 2003, Pavy-Le Traon, Heer et al. 2007).  148 
Therefore to maintain the greatest level of transferability to astronauts and in keeping with 149 
our other systematic reviews only bed rest studies that stated they were simulating human 150 
spaceflight were considered.  No clinical bed rest situations such as critical care were 151 
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included as they would likely have confounding co-morbities and not transfer well to 152 
astronauts.   All participants in the included bed rest studies were healthy at baseline, 153 
however, no exclusion was made relating to baseline level of physical condition beyond 154 
being healthy. Only control group data were relevant, therefore no inclusion criteria were 155 
based on interventions. Control groups had to be inactive and not undergo any type of 156 
intervention.  Included studies had to report outcomes relating to muscles.  For completeness 157 
of reporting the current state of the evidence base and avoid introducing selection bias, no 158 
exclusion was made based on type of outcome or amount of data.  The evidence based led 159 
outcomes were determined from pre-scoping and the main review searches and were grouped 160 
for analysis as cross-sectional area, volume, shape, size, activity, power, performance and 161 
joint torque and forces at either a regional or global level.  Included studies had to be 162 
randomised controlled trials (RCT), controlled clinical trials (CT), longitudinal, interrupted 163 
time series or before and after studies. 164 
2.2. Systematic review protocol 165 
2.2.1. Search strategy, data sources, studies sections and data extraction 166 
A range of relevant terms grouped by main search terms were constructed using Boolean 167 
logic (astronaut*, spaceflight, space flight, space*, weightless*, microgravity, micro gravity, 168 
bed-rest, bedrest, bed rest, dry immersion, muscle*, strength*) to search the following 169 
databases up to July 2017: Pubmed, CINAHL, Web of Science, NASA Technical Reports 170 
Server and The Cochrane Collaboration Library. No restrictions on type of bed rest or 171 
publication dates were applied, and due to the inability to use ‘Boolean logic’ on the NASA 172 
Technical Reports Server, the strategy was adapted to keyword searches. The full search 173 
strategy is available in Table 1. 174 
 *** insert table 1 here *** 175 
Initial screening was performed using abstracts and titles by two authors (MV and AW), 176 
blinded to each other’s decisions, using Rayyan (https://rayyan.qcri.org/) (Ouzzani, 177 
Hammady et al. 2016).  Rayyan also automatically detects duplicate studies and data and all 178 
flagged potential duplication was assessed by agreement of three blinded authors. Where 179 
there was any disagreement whether the study met the inclusion criteria from initial screening 180 
the full text was obtained. A third author (NC) was used to resolve disagreements of 181 
included/excluded studies. An adapted version of the Aerospace Medicine Systematic 182 
Review Group (AMSRG) ‘Data extraction form’, version 2, July 2017, (AMSRG 2018) was 183 
used by two authors (MV and NW) to extract data from each paper, and disagreements were 184 
discussed by three authors (AW, NW and MV) to reach consensus. 185 
2.3. Data analysis 186 
2.3.1. Quality assessment 187 
 The Quality in Prognostic Studies (QUIPS) tool was used to assess risk of bias of all 188 
the included studies, with ‘H’, ‘M’ and ‘L’ showing high, moderate and low risk respectively, 189 
using pre-defined published definitions for each level (Hayden, van der Windt et al. 2013).  190 
Risk of bias results were used to comment on the current quality and completeness of the 191 
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evidence base and do not change how studies were treated during analysis. As per published 192 
recommendations, only studies that were rated low risk of bias in all QUIPS domains were 193 
deemed as low risk overall (Hayden, van der Windt et al. 2013).  The AMSRG ‘Tool for 194 
Assessing Bed Rest Methods’ (Winnard and Nasser 2017a, Winnard and Nasser 2017) was 195 
used to assess the bed rest methodological quality, and transferability to astronaut 196 
populations, of all included studies, with ‘y’ indicating the point was met, ‘n’ not met and ‘?’ 197 
unclear.  This is a relatively new tool, yet to be validated, that has been used in several other 198 
reviews (Richter, Braustein et al. 2017, Winnard, Nasser et al. 2017) and the development of 199 
the tool is explained in Winnard et al (2017).  200 
2.3.2. Main analysis 201 
Effect sizes (Hedges’ g) were calculated between pre and post bed rest values for each 202 
outcome individually without an overall pooled effect. Hedges’ g was used to bias correct for 203 
the typically small sample sizes, as only control group data from µG simulation studies were 204 
eventually included.  The reported data set that was as close to immediate pre and the end of 205 
bed rest was used for the analysis.  No exclusion or analysis variation was made based on the 206 
individual study analysis methods.  The pooled standard deviation for Hedges’ g was 207 
calculated using the root mean square of the pre and post group standard deviations. This 208 
version does not specifically include the sample size (n), preventing any complications that 209 
could arise from inflating n when both group means are from the same sample.  Results were 210 
first sub-grouped by outcome measure type and then by muscle group before being listed in 211 
order of ascending days spent in simulated µG.  Individual effects sizes were calculated and 212 
plotted in figures for each outcome at every time point where data were available.  To enable 213 
a brief overview of the large data set to also be provided, an unweighted mean effect at each 214 
common time point within each muscle group was used to provide a summary result.  This 215 
was only done when more than one study assessed the same outcome at the same time point.  216 
These statistics were chosen due to data being from the same sample rather than a separate 217 
intervention and control group, thus making a traditional weighted effects meta-analysis 218 
pooling inappropriate.  Traditional meta-analysis assumes two different sets of individuals in 219 
each group (Higgins and Green 2011) meaning a violation of underlying assumptions would 220 
have occurred if applied to this review.  The summary unweighted mean, while being a less 221 
robust statistic, enabled an overarching overview to be reported in addition to each individual 222 
effect size, and overlaid on the figures, without violating statistical assumptions.  95% 223 
confidence intervals were calculated for individual and unweighted group means.  Readers 224 
should note that due to varying effect sizes across the various muscles and groupings, the 225 
effect size axis scale varies accordingly throughout the figures. 226 
The point at which effects consistently reached a magnitude of 0.6 (moderate) or 1.2 (large) 227 
was highlighted as a time point when a worthwhile mechanistic change had occurred 228 
(Hopkins, Marshall et al. 2009).  Plots of all individual effects and 95% confidence interval 229 
tails, in order of ascending days in simulated µG, were overlaid with the mean effect and 230 
polynomial trend line of the mean effects.  A polynomial trend allowed for the trend line to 231 
curve in case of progressively worsening, or plateauing patterns.  In cases where data were 232 
lacking and varied (spanning more than one effect size cut off between data points), the trend 233 
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line was highlighted as likely unreliable in the results section, meaning more data should be 234 
collected before a reliable trend can be established.  The limited data sets are however still 235 
included for completeness of reporting the current state of the evidence base and highlight 236 
both minimal data areas and research gaps.  The mean effect summary and trend line were 237 
only used to visually highlight the time point at which the mean effects passed the 0.6 and 1.2 238 
magnitude point.   A funnel plot of all the mean effects plotted against study size was used to 239 
show potential publication bias. 240 
2.3.3. Sub group analysis  241 
Ten sub groups were created based on the measurement methods units used for each for 242 
analysis as follows (with original units measured in): (1) contractile work capacity (J), (2) 243 
cross sectional area (mm2, cm2), (3) muscle activity (µV, mV, normalised), (4) muscle 244 
thickness (mm, cm), (5) muscle volume (cm3), (6) maximal voluntary contraction force 245 
during one repetition maximum (kg, N, Nm) (7), peak power (W), (8) performance based 246 
outcomes (including endurance time, jump power, force, velocity height and acceleration, sit 247 
to stand time, centre of mass variation and sprint time)(s, mm, cm, m, W/kg), (9) power 248 
(rad·s-1, m.s-1) and (10) torques and strength (Nm, ft-lb).  Within each subgroup data were 249 
further sub-grouped for analysis by major muscle groups.  For completeness of reporting, any 250 
measures that did not fit within major muscle groupings were grouped for analysis and 251 
reported as either “other lower limb”, “other trunk” or “other upper limb” outcomes, to 252 
enable every outcome measure extracted from included studies to be reported in the results.  253 
The outcomes included in the “other” groupings are listed in the text. 254 
3. Results 255 
3.1. Study selection, characteristics and risk of bias 256 
In total, 112 studies were included after duplicates removed, all of which were screened for 257 
inclusion into the analysis.  There were 37 not included in the analysis due the reasons 258 
provided in the PRISMA flow diagram (Figure 1).  Therefore, 75 studies (Table 2) were 259 
included, producing 922 individual effect sizes across all sub groups and outcomes.  All 260 
studies were bed rest µG simulations as no astronaut studies to date included an inactive 261 
control group exposed to µG due to space agency recommended exercise programmes.  There 262 
is no comparison descriptor column in table 2 as we only considered control groups who had 263 
no intervention, treated as before and after simulated µG exposure comparisons.  The most 264 
common bed rest duration was 60 days, with shortest and longest durations being seven and 265 
120 days, respectively.  The most common study design was RCT.  Most of the studies 266 
scored four on the bed rest quality score, with the highest score being six, and the lowest 267 
score was two.  Only three studies were assessed to have a low risk of bias.  As only 268 
intervention studies’ control group data were included and no actual prognostic studies were 269 
found and included, question three on the QUIPS about prognostic factors was rated as n/a 270 
for all the included studies.  A rating for question 3 would have been provided had any actual 271 
prognostic studies been found and included.  However, for this review, time in µG can be 272 
considered the prognostic factor and the quality of the µG simulation was critiqued in detail 273 
within the bedrest quality scores.  There is some asymmetry in the funnel plot in Figure 2, 274 
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suggesting potential publication bias toward studies reporting decreases in muscles, however 275 
there are studies, including smaller ones, that do report an increase.  Fourty five studies 276 
specified a time period ahead of the bed rest period in which baseline measures were 277 
recorded ranging from 1-21 days.  Of these, 11 (Greenleaf, Van Beaumont et al. 1983, 278 
Dudley, Duvoisin et al. 1989, Greenleaf, Bernauer et al. 1989, Ellis, Kirby et al. 1993, 279 
Greenleaf, Lee et al. 1994, Ferrando, Stuart et al. 1995, Portero, Vanhoutte et al. 1996, Muir, 280 
Judex et al. 2011, Lee, Schneider et al. 2014, English, Mettler et al. 2016, Schneider, Lee et 281 
al. 2016) stated utilising a pre-bed rest ambulatory control period in their methods section.  282 
However it was not clear in any of the studies what the control period involved or if there was 283 
any pre-bed rest deconditioning that was measured or adjusted for.  One study, (Mulder, 284 
Gerrits et al. 2008) measured baseline outcomes on day 4 of bed rest and acknowledges this 285 
could have led to underestimating the effect of bed rest, especially for time sensitive 286 
outcomes such as those associated with muscle. Full data tables for results per muscle are 287 
available in supplementary data tables as indicated in each results sub-section.  The raw data 288 
supporting the conclusions of this manuscript will be made available by the authors, without 289 
undue reservation, to any interested parties. 290 
*** insert figure 1 here*** 291 
***insert table 2 here** 292 
***insert figure 2 here*** 293 
3.2. Synthesised findings 294 
3.2.1. Muscle volume 295 
All muscle volumes decreased over time.  Moderate effects were becoming apparent by 14 296 
days and large by 28 days.  Very little data were available for Hip Flexor, Gluteal, Multifidus 297 
and Erector Spinae muscles, where a moderate or greater effect was never reached for Hip 298 
Flexors and Erector Spinae muscles and only a moderate effect was apparent by 27 and 90 299 
days for Gluteal and Multifidus muscles, respectively.  Other lower limb muscles that 300 
included Gracilis, Sartorius, Piriformis, Obturators and Pectineus muscles, reached a 301 
moderate effect by 14 days.  Other trunk muscles that included Levator Scapulae, Longus 302 
Colli, Sternocleidomastoid and Scalene muscles never reached a moderate effect.   The 303 
breakdown of individual volume effects per muscle is available in supplementary data Table 304 
3 and associated summary plots in Figure 3.  305 
***insert figure 3 here*** 306 
3.2.2. Muscle cross sectional area  307 
All muscle cross sectional areas decreased over time.  Moderate effects were apparent by 14 308 
days and large by 28 days.  The same effect time points were found for other lower limb 309 
muscles that included Gracilis and Sartorius muscles and total thigh and calf cross sectional 310 
area.   Very little data were available for Hip Flexor, Gluteal, Hamstring and Hip Adductor 311 
muscles where a moderate or greater effect was never reached.  Multifidus and other trunk 312 
muscles, including Quadratus Lumborum and combined Multifidus and Erector Spinae cross 313 
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sectional area, only reached a large effect by 60 days.  Upper limb muscle outcomes 314 
consisted of forearm muscle cross sectional area which only reached a large effect after 89 315 
days.   The breakdown of individual cross sectional area effects per muscle are available in 316 
supplementary Table 4 and associated summary plots in Figure 4.  The polynomial trend for 317 
Dorsi Flexor muscles appeared to be unreliable.  318 
***insert Figure 4 here*** 319 
3.2.3. Torques and strength 320 
Torques and strengths decreased over time.  Moderate effects became apparent by 14 days for 321 
Quadriceps muscles only.  Additional moderate effects became apparently by 30 days and 322 
large effects by 35 days.  Dorsi Flexor, Hamstring, Hip Extensor, Hip Flexor, other trunk and 323 
other upper limb muscles never reached a large effect.  Other trunk muscles included trunk 324 
flexors and extensors tested in combination within functional movements.  Upper limb 325 
muscles included elbow flexor and extensor muscles and shoulder abductor and adductor 326 
muscles.  The breakdown of individual torques and strength effects per muscle is available in 327 
supplementary Table 5 and associated summary plots in Figure 5.   The polynomial trend for 328 
Dorsi Flexor muscles appeared to be unreliable after 60 days. 329 
***insert Figure 5 here*** 330 
3.2.4. Contractile work capacity 331 
Although there are very little available data for contractile work capacity it appears to 332 
decrease over time.  Moderate effects became apparent by 14 days in Plantar Flexor and 333 
Quadriceps muscles.  However, this is based on only one study for each muscle at 14 days.  334 
The breakdown of individual contractile work capacity effects per muscle is available in 335 
supplementary Table 6 and associated summary plots in Figure 6.  Data were limited for all 336 
muscles. 337 
***insert Figure 6 here*** 338 
3.2.5. Muscle thickness 339 
Muscle thickness decreased over time.  Moderate and large effects became apparent by 14 340 
days.  There were very little data for Plantar Flexor, Dorsi Flexor and Quadriceps muscles, 341 
showing Dorsi Flexor muscles reached a moderate effect by 35 days and only Plantar Flexor 342 
and Quadriceps muscles reached a large effect by 35 days.  Internal Oblique muscle reached a 343 
moderate effect at 14 days.  Erector Spinae muscle was similar to Internal Oblique muscle, 344 
but only reached a borderline moderate effect within the available data.  Upper limb muscles 345 
data only included Biceps Brachii muscle thickness, reaching a moderate effect by 35 days.  346 
The breakdown of individual muscle thickness effects per muscle is available in 347 
supplementary Table 7 and associated summary plots in Figure 7.  348 
***insert Figure 7 here*** 349 
3.2.6. Peak power 350 
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Peak power decreased over time.  Large effects became apparent by 56 days for jump power 351 
and 62 days for Plantar Flexor and Quadriceps muscles.  There was insufficient data to 352 
determine a time point for when any moderate effects were reached.   The breakdown of 353 
individual peak power effects per outcome is available in supplementary Table 8 and 354 
associated summary plots in Figure 8.   355 
***insert Figure 8 here*** 356 
3.2.7. Muscle activity 357 
Muscle activity (via electromyography) generally decreased over time, however a transient 358 
increase was seen in Plantar Flexor, Dorsi Flexor and Quadriceps muscles and only at 20 359 
days.  In Plantar Flexor and Quadriceps muscles, muscle activity decreased again after 20 360 
days, there were no data for Dorsi Flexor muscles beyond 20 days to establish a post 20 day 361 
trend.  Moderate effects were apparent in upper limb muscle groups by 15 days but not until 362 
90 days for Dorsi and Plantar Flexor muscles which were the only muscles with data at the 90 363 
day point.  The breakdown of individual activity effects per muscle is available in 364 
supplementary Table 9 and associated summary plots in Figure 9. 365 
***insert Figure 9 here*** 366 
3.2.8. Maximal voluntary contraction during one repetition maximum 367 
Maximal voluntary contraction during one repetition maximum decreased over time except 368 
for other upper limb outcomes that remained mostly unchanged as far as data were available 369 
up to 45 days.  Moderate effects became apparent by seven days and large effects by 35 days.  370 
Other lower limb outcomes that included maximal isometric force during supine squat, hip 371 
extensor force and legs total work never reached a large effect, but had no data available 372 
beyond 35days.   The breakdown of individual MVC during one repetition maximum effects 373 
per muscle is available in supplementary Table 10 and associated summary plots in Figure 374 
10.  The polynomial trend for Hamstring muscles appeared to be unsafe after 20 days. 375 
***insert Figure 10 here*** 376 
3.2.9. Power 377 
Power decreased over time.  Moderate effects became apparent by 7 days and large effects by 378 
20 days, although these were only seen in the Quadriceps muscle data.  Hamstring, Hip 379 
Flexor and upper limb muscles that included elbow flexors and extensors reached moderate 380 
effects by 20 days.  Plantar Flexors never reached a moderate effect but data were only 381 
available at 14 days.  Other trunk muscles included trunk flexors and extensors tested in 382 
combination within functional movements.  The breakdown of individual power effects per 383 
muscle is available in supplementary Table 11 and associated summary plots in Figure 11.  384 
***insert Figure 11 here*** 385 
3.2.10. Performance based 386 
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Performance based outcomes all worsened over time, as although sit to stand, balance and 387 
sprint time outcomes all had positive effects, this was considered a worsening effect within 388 
these measures.  Endurance reached a large effect by 14 days, jumping a moderate effect at 389 
42 days and large by 44 days, sit to stand and balance reached large effects by 60 days and 390 
sprint time by 62 days.  Data for most outcomes were only available for one time point and so 391 
trends over time for individual outcomes are not able to be determined.   The breakdown of 392 
individual performance based effects per outcome is available in supplementary Table 12 and 393 
associated summary plots in Figure 12.  It should be noted that while these outcomes are 394 
grouped as being performance based for this review, they may differ and each individual 395 
measure should be considered on its own merit. 396 
***insert Figure 12 here*** 397 
4. Discussion 398 
 399 
4.1. Summary of main findings 400 
The main finding of the review was that muscle cross-sectional area, volume, shape, size, 401 
activity, power, performance, torque and force-based outcomes, at either regional or global 402 
level, all decline over time, based on the current evidence base.  Moderate effects became 403 
apparent in the following order: power and MVC during one repetition maximum (7 days), 404 
followed by volume, cross sectional area, torques and strengths, contractile work capacity, 405 
thickness and endurance (14 days), then muscle activity (15 days).  Large effects became 406 
apparent in the following order: volume, cross sectional area (28 days) torques and strengths, 407 
thickness (35 days) and peak power (56 days).  No large effects were found for muscle 408 
activity. There were limited data for contractile work capacity and no large effects were 409 
apparent.  In general, lower limb and trunk muscles appeared to decline more rapidly than 410 
upper limb muscles. Locomotion muscles such as Plantar Flexor and Quadriceps muscles 411 
also generally appeared to decline more rapidly than other muscles groups and with larger 412 
effect sizes. 413 
4.2. Findings within context of Human space mission profiles 414 
Human spaceflight missions differ in duration, so results have to be placed into the context of 415 
mission profiles and operationally important considerations.  Operationally, performance-416 
related measures such as power, MVC, torques and strengths are considered most critical.  In 417 
terms of mission profiles, typical ISS missions involve approximately 180 days in µG 418 
(Bryant, Meza et al. 2017).  The provision of time for exercise CM is mandated for these 419 
missions and developments have led to improved efficacy over the lifetime of ISS (Trappe, 420 
Costill et al. 2009, Ploutz-Snyder 2013, Hackney, Scott et al. 2015).  Assuming that the rate 421 
of change during bed rest is reasonably transferable to that experienced in G, the results of 422 
this systematic review suggest that large effects would be apparent within a 180 day ISS 423 
mission if no exercise CM were employed.  That ISS astronauts are able to complete missions 424 
without problems from muscle deterioration and successfully return to Earth may provide 425 
some level of evidence with which to judge current countermeasures as effective. However, 426 
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the focus of this review is exploration beyond Low Earth Orbit. Lunar and Martian 427 
(exploration) mission profiles were defined in the HUMEX study (Horneck, Facius et al. 428 
2006) that modelled exploration mission durations including transit times in µG and 429 
planetary stay times in low (<1G) gravity (Figure. 13).  HUMEX defined three scenarios, 430 
including a Lunar mission with a 180 day surface stay (Horneck, Facius et al. 2003) and two 431 
Mars missions with either a 30 or 400 day surface stay (Horneck, Facius et al. 2006).  In 432 
HUMEX, inter planetary transit time in µG was five days for Lunar missions and 203-213 433 
days for Mars.  434 
***insert Figure 13 here*** 435 
4.2.1.1. Mars 436 
It is clear from the findings of this review that changes in muscle outcomes, including 437 
performance related measures, with large effects would be observed if no CM were 438 
performed during a 200+ day transit to Mars.  A risk assessment (Gernand 2004) has 439 
highlighted that decreased muscle mass, strength and endurance is likely to lead to inability 440 
to complete mission critical tasks such as exiting a spacecraft on landing, performing 441 
strenuous extra vehicular activity and being functional during increased Gz loading on non-442 
Earth planetary surfaces where a landing support and rehabilitation team may not be 443 
available.  Therefore, effective CM to prevent muscle deterioration are likely going to be 444 
required for Mars missions unless absolute strength mission requirements can be reduced or 445 
eliminated, to mitigate risks of crews being unable to perform mission critical tasks and 446 
continue to function safely on arrival at Mars.  However, based on the occurrence of large 447 
effect sizes in the present results only after 28-35 days, exercise CM ‘holidays’ might be 448 
considered during Mars transits/orbits to save resources if agencies were confident that 449 
moderate changes in muscle performance could be reversed using in-flight exercise 450 
equipment and prescriptions. 451 
4.2.1.2. Moon 452 
The results of this review suggest that exercise CM might not be required during a five day 453 
Lunar transit period, as moderate effects on muscle are not likely to be apparent until 7 days.  454 
The initial changes in power and MVC might not be functionally limiting enough to risk 455 
mission success, compared to muscle size, strength and endurance effects that do not reach a 456 
moderate size until 14 days.   Therefore, further investigation of any effects within the 457 
expected Earth-Lunar transit period, considered against minimal clinically worthwhile and 458 
mission critical magnitude changes, may be useful to confirm this finding.  As a Lunar 459 
landing may occur at 8 days in the HUMEX models, the pre-flight strength of crew and the 460 
absolute strength and functional requirements of Lunar landing activities would need to be 461 
considered when deciding whether or not employ exercise CM prior to attempting a landing.  462 
While not employing exercise CM might be considered for the Earth-Lunar transit period, a 463 
recent systematic review of biomechanical responses to reduced gravity (Richter, Braustein et 464 
al. 2017) showed  that exercise CM would likely be needed during stays on the planetary 465 
surfaces of both Moon (0.16g) and Mars (0.38g).  As time in both µG and low gravity 466 
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accumulates over the entire mission duration (196-d in total for the HUMEX model), exercise 467 
CM are also likely to be needed during the return to Earth transit.  However, not using 468 
exercise CM on the return transit might be considered if key muscle outcomes could be 469 
maintained at, or restored to, pre-mission levels by the end of a Lunar surface stay.  Based on 470 
the occurrence of large effect sizes in the present results, in an off-nominal situation, such as 471 
an emergency, a longer period, possibly up to around 30 days, without exercise CM might be 472 
considered if the risks of moderate-large effects can be managed in some other way, for 473 
example, knowing support and a full rehabilitation programme are available at the destination 474 
arrival site.  As with Mars missions, for long Lunar orbital missions with extended periods in 475 
µG, an exercise CM ‘holiday’ of the same duration might be considered if agencies were 476 
confident that moderate changes in muscle performance could be reversed in-flight. 477 
4.2.2. Individuals more susceptible to µG induced muscle changes 478 
An individual with a relativiely lower muscle outcome measure may be more susceptible to 479 
experiencing a negative functional impact of negative changes in these outcomes compared to 480 
someone with greater initial measures.  It is expected that most missions will require an 481 
absolute (minimal) level of strength to achieve mission critical tasks such as donning/doffing 482 
and standing up/moving whilst wearing a space suit in low gravity, hatch opening, and 483 
pulling/dragging a fellow crew member wearing a space suit during an emergency.  The 484 
absolute level is defined as the precise required strength outcome in raw units to achieve a 485 
task, as opposed to considering relative changes with effect size or percentage changes.  A 486 
relative (%) reduction in strength will make all tasks with an absolute strength requirement 487 
more challenging for all individuals, but the biggest impact will be felt by those who have a 488 
lower initial level of absolute strength.  For example, a strong individual might be able to lose 489 
30% of their pre-flight strength and still comfortably achieve a mission critical task (and also 490 
still be stronger than a weaker individual was prior to flight), whereas a weaker individual 491 
might already be close to their physical limit during this task without any deconditioning.  492 
Operationally, having an estimate of the most rapid possible rate of change in muscle 493 
outcomes may be useful in the case of a crew member with low pre-flight absolute strength, 494 
or an individual highly susceptible to µG adaptation.  In the present study, the most extreme 495 
negative value within the confidence interval for each outcome provides an estimate of the 496 
most extreme worst likely true value that might be encountered with exposure to µG.  Based 497 
on this estimation, the results of this analysis suggest that the change experienced by an 498 
individual astronaut might reach a large effect size in some muscles within a seven day lunar 499 
transit period for volume, cross sectional area, contractive work capacity, thickness, power 500 
and MVC.  However, the confidence intervals are wide due to the small sample sizes across 501 
the current evidence base, so this estimate should be treated with caution as it may be 502 
exaggerated.  Individual effects are difficult to determine in a transferable way to the true 503 
population from the data currently available or from individual case studies.  Ideally, a 504 
population selected for their increased susceptible to unloading/µG-induced muscular 505 
adaptation should be studied in a long-duration µG analogue to produce a representable 506 
average effect that could be transferred to the true population with more reasonable 507 
confidence.  Until such data are available, estimating the maximum rate of decline in an 508 
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individual in response to µG exposure of such a duration will remain difficult.  In addition, 509 
consideration would also be needed should an individual be selected to perform some tasks in 510 
a mission that are not considered mission critical, but are essential to other mission goals.  It 511 
may be that checking for susceptibility to outcomes that are linked more strongly to mission 512 
success is checked and made part of astronaut eligibility screening, it could also be any more 513 
susceptible mission critical individuals undergo more rigorous preflight and inflight training 514 
protocols or consider use of other more removed countermeasures beyond the scope of this 515 
review. 516 
Exercise countermeasure development may want to consider focussing on those which might 517 
best address the more susceptible outcome changes in this review, volume, cross sectional 518 
area, contractive work capacity, thickness, power and MVC while also ensuring any proposed 519 
exercises are tailored to tasks considered critical, such as donning/doffing and standing 520 
up/moving whilst wearing a space suit in low gravity, hatch opening, and pulling/dragging a 521 
fellow crew member wearing a space suit.  The impact of any chosen exercise types on future 522 
spacecraft exercise hardware would also need further consideration.  Future research should 523 
consider identifying exercise countermeasures that would best address the more susceptible 524 
outcomes and be feasible with any technical constraints of new space vehicles planned for 525 
use within Moon and Mars missions. 526 
4.2.3. Countermeasure requirement 527 
As CM are likely to be needed on the return trip from both Moon and on the journeys to and 528 
from Mars, such CM will need developing.  Countermeasure devices should support lower 529 
limb and trunk muscle exercise as these decline earlier than other body regions and are 530 
essential for locomotion and for spinal function on return to G loading (Bamman 1996, Pavy-531 
Le Traon, Heer et al. 2007, Evetts, Caplan et al. 2014, Stokes, Evetts et al. 2016, Winnard, 532 
Nasser et al. 2017a).  Based on the results of the present study, if exercise CM are used 533 
during very short missions/transits (e.g. up to seven days), devices should support exercise 534 
that maintains power and maximal force production, as moderate effects appeared early in 535 
these performance outcomes. Up to around 15 days, exercise CM might need only to prevent 536 
moderate size effects in muscle.  Consideration could be made around if lower intensity 537 
exercise, or potentially a break in countermeasures would be safe.  .  However, once µG 538 
exposure duration reaches around 30 days and above, large effects in muscle will likely need 539 
to be managed and this would likely require devices/prescriptions optimised within the 540 
constraints of the vehicle/habitat.   541 
This pattern fits current European Space Agency (ESA) ISS Long Duration Mission (LDM) 542 
exercise prescriptions (Petersen, Jaekel et al. 2016) that include an initial 20-day 543 
familiarisation phase to allow crew to adjust to exercise in µG and minimise injury risk, in 544 
which exercise intensity is moderate compared to pre-flight maximum capacity.  However, as 545 
there is currently no systematic measurement of muscle performance in-flight, the impact of 546 
this period of lower intensity exercise on overall changes in muscle during an LDM is 547 
unknown.  It is also unclear if crew members may have had better results at the end of a 548 
mission had they begun exercising more intensely earlier in the mission. Following the 20-549 
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day familiarisation period, exercise prescriptions are increased in intensity to 80 %+ maximal 550 
capacity.  In the final 15-30 days of a long duration mission (greater than 49 days) intensity is 551 
kept high, but focus on resistance and running exercises.  In flight resistance exercise 552 
prescriptions for European astronauts also focus on lower limb muscles (squats, heel raises, 553 
deadlifts) ESA has found are most susceptible to µG induced changes from (non systematic) 554 
measures that have been taken (Petersen, Jaekel et al. 2016).  Similar exercise prescriptions, 555 
focussing on lower limb muscles and maintaining outcomes already highlighted in this 556 
review, might form a good basis for initial planning for any exercises required for Lunar and 557 
Mars missions.  Additionally, research on preventing deconditioning of older adults might 558 
also be useful as preventing loss of power in functional lower limb muscles is important in 559 
this population and simple loading exercises  have shown helpful in this context (Byrne, 560 
Faure et al. 2016).  It should also be noted, however, that a systematic review of in-flight CM 561 
for maintaining spinal health in µG found that, while resistance based exercises helped 562 
prevent muscle changes, they did not help with non-muscle outcomes such as spinal 563 
morphology (Winnard, Nasser et al. 2017a).  Moreover, a number of other physiological 564 
systems/organs also adapt to µG, including bone and aerobic capacity, but the efficacy of 565 
resistance exercise during gravitational unloading on them is unknown as systematic reviews 566 
similar to the present study have yet to be performed. Therefore, while the recommendations 567 
of this review are expected to help plan CM for muscle changes, additional holistic 568 
consideration of other physiological systems will likely be required.  Finally, any CM 569 
development for exploration missions will also have to consider constraints of space vehicles 570 
that will be used, such as available physical space, limited number of devices that can be 571 
included in the space craft, consumables, generation of heat, carbon dioxide and vibration, 572 
which are likely to be more restricted than the ISS (Hackney, Scott et al. 2015).  Before any 573 
pause in exercise countermeasures could be taken, the results of this review would need to be 574 
validated in microgravity and ideally actual astronauts through experimental studies.  No 575 
such published studies of astronauts not performing exercise to document muscle changes 576 
over the time frames considered in this review was found.  Space agencies and researchers 577 
would also need to consider the ethical implications and acceptability of any such study.  578 
4.3. Completeness and quality of current evidence 579 
There were missing and limited data across all the outcome measure subgroups, and gaps in 580 
the evidence base were clearly shown in the results tables.  There was a lack of standardised 581 
time points at which measures were recorded, even across studies reporting the same outcome 582 
measures.  Limited data were found repeatedly for Gluteal and Hip Flexor muscles across 583 
several outcome measure subgroups. Data were lacking for contractile work capacity, muscle 584 
thickness and peak power outcome measures where further research is recommended to 585 
validate the trends seen over time in the current evidence base.  No patient reported outcome 586 
measures have been reported across the bed rest studies, meaning it is unclear how relevant 587 
the measures are to patients (in this case astronauts) (Dawson, Doll et al. 2010, Nelson, 588 
Eftimovska et al. 2015).  In addition, only seven out of the 75 analysed studies considered 589 
functional performance based outcomes that are more likely to be directly relevant to 590 
astronauts.   While strong efforts on behalf of space agencies to standardise bed rest studies 591 
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has occurred including listing required surrogate measures(Sunblad, Orlov et al. 2014), 592 
patient reported outcomes such as their ability to perform a task felt of value to them, remain 593 
missing on the whole. It is recommended that the scientific and space medical operations 594 
communities agree on set times points at which outcome measures should be tested to enable 595 
easier comparisons across studies and for overall trends to be more easily identifiable.  While 596 
ESA requires agency bed rest studies to be performed to set standards, it might be beneficial 597 
to consider running a specific initiative in the wider Aerospace Medicine field to establish 598 
core outcome sets relevant to space medicine operations that should then be used in all 599 
associated research.  This could be based on recommending use of standard space agency 600 
developed tests such as functional and Field Test parameters developed by NASA and Russia  601 
The Core Outcome Measures in Effectiveness Trials (COMET) is an example initiative that 602 
facilitates development and application of core outcome sets and research has been published 603 
on how to reach consensus using such an approach (Prinsen, Vohra et al. 2014).   It is also 604 
recommended that patient reported outcome measures, and increased reporting of functional 605 
performance based outcome measures, be included in both future research and space medical 606 
operations to ensure that outcome measures are assessing phenomena that are relevant to 607 
astronauts.   This recommendation echoes a recent European Space Agency topical team 608 
report that also found patient reported outcome measures not being used in space medicine 609 
research and operations (Stokes, Evetts et al. 2016).  The report recommended the use of such 610 
outcomes and suggested potential for development of new such outcome measures 611 
specifically for space medicine with operational space medicine input to ensure relevance 612 
across research and clinical settings.  It would be of further benefit if clinically worthwhile, 613 
or concerning, changes were defined for key outcome measures, so that results can be placed 614 
into a clinically meaningful context.  Reporting results based on clinically meaningful raw 615 
changes would likely be more informative to operational decisions compared to the more 616 
mechanistic null hypothesis tests, effect size or percentage change measures currently used.  617 
The high risk of bias and lack of core outcome measure sets means that the conclusions 618 
reached by this review should be treated with some caution.  A bed rest study could be 619 
performed to confirm the findings of this review. If performed, the study would ideally be a 620 
randomised controlled trial comparing inactive bedrest with controls not performing bedrest 621 
but controlled for all potential confounding factors.  For example, exercise and any other 622 
types of muscle interventions would need to be strictly controlled for the period of the study.  623 
The bed rest element would ideally comply with all aspects of the AMSRG bed rest quality 624 
tool to improve transferability of results to astronauts (Winnard and Nasser 2017).  Finally, 625 
all modifiable risk of bias elements would need controlling and a risk of bias tool for 626 
randomised controlled trials, such as provided by Cochrane (Higgins, Altman et al. 2011), 627 
could be used as a guide to check what elements need to be controlled to minimise bias risks.    628 
Most of the studies scored four on the bed rest tool, with no studies scoring a full seven 629 
points, although thirteen studies scored six.  The reasons for marking studies down was 630 
mostly due it being unclear if criteria had been met rather than clearly failing a point.  The 631 
most common unclear criteria was related to restricted sunlight exposure followed by 632 
ensuring a fixed daily routine.  The high risk of bias results were most commonly caused by 633 
not clearly showing how confounding factors were managed and providing adequate 634 
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description of participation.  The participation domain considers participant eligibility 635 
criteria, source of participants, baseline descriptions, description of sampling frame and 636 
recruitment, description of period and place of recruitment and inclusion/exclusion criteria 637 
(Hayden, van der Windt et al. 2013).  The sunlight exposure criteria has more impact on bone 638 
outcomes (Holick 2004) due to its role in vitamin D levels within human bone homeostasis 639 
(Tarver 2013) so might not be a large concern for the muscle outcomes presented in this 640 
review.  However, it is recommended that future bed rest protocol information be clear on all 641 
the criteria assessed on the bed rest quality tool and especially on the fixed daily routine and 642 
restricted sunlight points, while also ensuring that information is provided about control of 643 
confounding factors to help reduce risk of bias and participation considerations.  In addition, 644 
studies that assess time sensitive outcomes, such as muscle (in which the results of this 645 
review show effects of deconditioning can occur by 7 days), should report any potential for 646 
pre-bedrest deconditioning during familiarisation and baseline measure periods and any 647 
attempts to control for this.  There is potential that participants who are admitted to bed rest 648 
facilities several days in advance for control measures could decondition within this period.  649 
Some studies state including an ambulatory control period, but none report details of what 650 
this involved or if there was potential for pre-bed rest deconditioning to influence results. 651 
There was some asymmetry in the funnel plot showing potential publication bias towards 652 
studies reporting a decrease in muscle outcomes.  However, there were studies present on the 653 
increasing side of the plot, so the risk is not likely to be high.  In addition, it is expected that 654 
many of the muscle outcomes would decrease during a period of inactivity such as bed rest, 655 
therefore, it not surprising most studies reported decreases.  Therefore, while it appears a risk 656 
of reporting bias may exist, the presence of some studies reporting increases and the expected 657 
pattern of more decreases being reporting suggest this finding should be treated with caution 658 
and the potential risk is likely to be low.    659 
4.4. Limitations 660 
This review only considered muscle outcomes.  Spaceflight is known to affect many more 661 
human physiological systems including bone, cardiovascular and vestibular (Pavy-Le Traon, 662 
Heer et al. 2007).  These results alone, therefore, only provide a muscle based perspective.  663 
As typical meta-analysis statistics assume two independent groups (Higgins and Green 2011), 664 
a more basic effect size analysis without these assumptions had to be used due to only 665 
considering changes over time in the control group of each study.  Therefore, some caution 666 
should be taken as the mean effect sizes are not weighted and heterogeneity scores are not 667 
available.  However, as most studies had small sample sizes, a weighted result is not expected 668 
to produce largely different results.  Additionally, the findings of this review appear to match 669 
actual spaceflight findings and patterns, such as the European Space Agency exercise 670 
prescription for long duration missions that performs lower intensity exercises for the first 20 671 
days.  While actual measures are not taken during flight, the 20 days has so far not resulted in 672 
any mission critical functional decline (Petersen, Jaekel et al. 2016).  The 20 day period 673 
would fit with the findings of this review that only moderate effects would be expected 674 
before 28 days and gives some partial validation, from actual astronaut data, to the findings 675 
of this review. The review is also broad and, in places, the variation around the outcomes 676 
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appears large suggesting heterogeneity of data may be high, although the large intervals could 677 
also be due to the small sample sizes that were a common feature of the included bed rest 678 
studies. Due to the broad data set that summarises the entire muscle evidence base, additional 679 
data on pre-bedrest fitness of participants was not extracted for analysis.  While studies were 680 
selected that had healthy adults undergoing spaceflight simulation bedrest, individual 681 
physical condition was not considered beyond this.  Therefore there may be some limitations 682 
to the transferability of astronauts who undergo training with space agencies prior to 683 
missions.  However, a broad summary of the entire current evidence base with basic effect 684 
size analysis was the best way to try to address the overarching research questions,look for 685 
high level trends and present a summary of the current state of the complete evidence base.  686 
4.5. Conclusions 687 
The results of this review suggest that moderate effects on a range of muscle function 688 
parameters may occur within 7-14 days of unloading, with large effects within 35 days. 689 
Combined with identification of muscle performance requirements for future exploration 690 
mission tasks, these data, may support the design of CM programmes to optimise their 691 
efficient use without compromising crew safety and mission success.  However, the data 692 
suggests CM are likely to still be needed for longer transit/orbital periods of 14-28+ days, 693 
such as a prolonged Lunar orbit, deep space exploration, or a Mars mission, as moderate 694 
effects occur between 7-14 days and large effects by 28 days for most muscle outcomes.  695 
However, if large effect sizes occur only after 28-35 days, to save resources, space agencies 696 
might consider short missions without exercise CM, or fixed periods of abstinence during 697 
longer µG exposures, if they could be confident that moderate changes in muscle 698 
performance could be reversed in-flight. Finally, several research gaps are highlighted for 699 
future bed rest studies in which standardised time points for measurements should be used 700 
and clear information provided on sunlight exposure control, fixed daily routine and control 701 
of any confounding factors.  702 
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43. (Kawashima, Akima et al. 2004) 760 
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Figure 1 PRISMA flow diagram of inclusion/exclusion process 
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Figure 2 Funnel plot of all effects 
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Figure 3 Effect size plots for muscle volume over time from individual (grey) and 
average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed 
line) effect magnitudes and average effect trend line overlaid. 
34 
 
 
Figure 4 Effect size plots for muscle cross sectional area over time from individual 
35 
 
(grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 
(dashed line) effect magnitudes and average effect trend line overlaid. 
36 
 
 
Figure 5 Effect size plots for torques and strength area over time from individual (grey) 
and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed 
line) effect magnitudes and average effect trend line overlaid. 
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Figure 6 Effect size plots for contractile work capacity over time from individual (grey) 
and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed 
line) effect magnitudes and average effect trend line overlaid.
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Figure 7 Effect size plots for muscle thickness over time from individual (grey) and 
average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed 
line) effect magnitudes and average effect trend line overlaid.
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Figure 8 Effect size plots for peak power over time from individual (grey) and average 
(black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect 
magnitudes and average effect trend line overlaid. 
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Figure 9 Effect size plots for EMG muscle activity  over time from individual (grey) and 
average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed 
line) effect magnitudes and average effect trend line overlaid. 
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Figure 10 Effect size plots for MVC during one rep max over time from individual 
(grey) and average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 
(dashed line) effect magnitudes and average effect trend line overlaid.
42 
 
 
 
Figure 11 Effect size plots for power over time from individual (grey) and average 
(black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed line) effect 
magnitudes and average effect trend line overlaid. 
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Figure 12 Effect size plots for performance based over time from individual (grey) and 
average (black) effect sizes at each time point, with 0.6 (dotted line) and 1.2 (dashed 
line) effect magnitudes and average effect trend line overlaid. 
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Figure 13 Mission profiles for 180 day surface stay Lunar mission (bottom) and 493 day 
surface stay Mars mission (top), adapted from HUMEX (Horneck, Facius et al. 2003, 
Horneck, Facius et al. 2006)  
45 
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Table 1 Search strategy for database literature search. 
Search number Term Keywords in Boolean logic format 
1 Microgravity “astronaut” OR “spaceflight OR “space flight OR 
“space*” OR “weightless*” OR “microgravity” OR 
“micro gravity” 
2 Bed rest “bed-rest” OR “bedrest” OR “bed rest” OR “dry 
immersion” 
3 Muscle “musc*” OR “strength*” 
4 Combined 1 AND 2 AND 3 
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Table 2 Characteristics of analysed studies  
 
 
  Bed rest quality tool 
T
O
T
 
QUIPS risk of bias tool 
Study(analysis cross reference no.) Design n Outcomes Days  1 2 3 4 5 6 7 1 2 3 4 5 6 OVERALL  
Akima et al., 20001 RCT 4 Cross-sectional area, torque, volume.  20 y ? ? y y ? y 4 M L n/a L H L H 
Akima et al., 20032 RCT 6 Cross-sectional area, torque. 20 y ? ? y y ? y 4 M L n/a L M L H 
Akima et al., 20053 RCT 5 Activity (EMG), volume, MVC.  20 y y ? y y ? y 5 M L n/a L M L H 
Akima et al., 20074 RCT 6 Muscle Volume. 20 y ? ? y y ? y 4 M L n/a L M L H 
Alkner and Tesch 20045 RCT 9 Volume, MVC, force, power, torque, activity (EMG). 90 y ? ? y y ? y 4 M L n/a L M L H 
Alkner et al., 20166 RCT 9 Activity (EMG), force,  90 y ? ? y y ? y 4 M L n/a L M L H 
Arbeille et al., 20097 RCT 8 Volume  60 y y ? y y ? y 5 L L n/a L M L H 
Bamman et al., 19978 RCT 8 MVC, activity (EMG), torque, Power, work. 14 y y ? y y ? y 5 L L n/a L M L H 
Belavy et al., 2007(a)9 RCT 10 
 
56 n y ? y ? ? y 3 L L n/a L H L H 
Belavy et al., 200810 RCT 10 Cross-sectional area.  56 ? y ? y ? ? y 3 L L n/a L H L H 
Belavy et al., 2009(a)11 RCT 10 Volume. 56 ? y ? y ? ? y 3 L L n/a L H L H 
Belavy et al., 2009(b)12 RCT 10 Volume.  56 ? y ? y ? ? y 3 L L n/a L H L H 
Belavy et al., 2010(b)13 RCT 9 Cross-sectional area  60 y y y y y ? y 6 H L n/a L H L H 
Belavy et al., 2011(a)14 RCT 9 Cross-sectional area 60 y y y y y ? y 6 M L n/a L M L H 
Belavy et al., 2011(b)15 RCT 9 Volume  90 y y ? y ? ? y 4 L L n/a L H L H 
Belavy et al., 2011(c)16 CO 7 Cross-sectional area, Muscle Signal Intensity 21 y ? ? y ? ? y 3 M L n/a L H L H 
Belavy et al., 201317 RCT 9 Volume 60 y y y y y ? y 6 H L n/a L H L H 
Belavy et al., 201618 RCT 8 Muscle Atrophy 56 ? y ? y ? ? y 3 L L n/a L H L H 
Berg et al., 199719 RCT 7 Torque, activity (EMG), angular velocity, fibre 
types/size, cross-sectional area 
42 y ? ? y y ? y 4 M L n/a L H L H 
Berg et al., 200720 RCT 5 MVC, Cross-sectional area  35 n ? ? y y ? y 3 H L n/a L H L H 
Berry et al., 199321 CO 6 Cross-sectional area 30 y ? ? y ? ? y 3 H L n/a L H L H 
Buehring et al., 201122 RCT 10 MVC, activity, Jump Power, Jump Height 56 n y ? y ? ? y 3 L L n/a L H L H 
Caiozzo et al., 200923 RCT 7 Torque, cross-sectional area 21 y ? ? y ? ? y 3 H L n/a L H L H 
Cescon & Gazzoni 201024 RCT 4 Single and Global motor unit conduction velocity 14 y y ? y y ? y 5 L L n/a L M L H 
Convertino et al., 198925 B&A 8 cross-sectional area 30 y ? ? ? ? ? y 2 H L n/a L H L H 
De Boer et al., 200826 B&A 10 Thickness  35 n ? ? y y ? y 3 M L n/a L H L H 
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  Bed rest quality tool 
T
O
T
 
QUIPS risk of bias tool 
Study(analysis cross reference no.) Design n Outcomes Days  1 2 3 4 5 6 7 1 2 3 4 5 6 OVERALL  
Dudley et al., 198927 B&A 7 Torque  30 y ? ? ? ? ? y 2 H L n/a L H L H 
Duvoisin et al., 198928 TS 3 Torque velocity  30 y ? ? ? ? ? y 2 H L n/a L H L H 
Ellis et al., 199329 CS 5 Thickness 30 y y y y y ? y 6 M L n/a L M L H 
English et al., 201130 B&A 8 Torque  60 n y y y y ? y 5 L L n/a L M H H 
English et al., 201631 RCT  9 Torque and work 14 ? y ? y y ? y 4 L L n/a L M L H 
Ferrando et al., 199532 B&A 6 Volume  7 ? y ? y y ? y 4 H L n/a L H L H 
Ferretti et al., 200133 TS 7 Cross-sectional area, jump power 42 y ? ? y y ? y 4 M L n/a L M L H 
Fu et al., 201634 TS 8 Activity (EMG), force. 45 y y ? y y ? y 5 M L n/a L M L H 
Funato et al., 199735 TS 10 Strength, velocity. 20 ? ? ? y ? ? y 2 M L n/a L H L H 
Gast et al., 201236 RCT 9 Jump height & power, sit-to-stand tests, sprint time, 
leg press (1RM) 
60 y y y y y ? y 6 L M n/a L M L H 
Germain et al., 199537 RCT 6 Torque 28 y ? ? y y ? y 4 M L n/a L H L H 
Greenleaf et al., 198338 RCO 7 Hand Grip Endurance 14 ? y ? ? ? ? y 2 H L n/a L H L H 
Greenleaf et al., 198939 RCT 5 Work, torque 30 y y ? y y ? y 5 M L n/a L M L H 
Greenleaf et al., 1994(a)40 RCT 5 Volume. 30 y y ? y y ? ? 4 M L n/a M H L H 
Holguin et al. 200741 RCT 11 Volume 90 Y Y ? Y Y ? Y 5 H L n/a L M L H 
Holt et al., 201642 RCT 8 Cross-sectional area. 60 y y y y y ? y 6 L L n/a L L L L 
Kawashima et al., 200443 B&A 10 Cross-sectional area. 20 n y ? y y ? y 4 H L n/a L H L H 
Koryak 1995(a)44 B&A 6 MVC, force, time to peak tension, total contraction 
time. 
120 y ? ? y y ? y 4 L L n/a L M L H 
Koryak 199645 B&A 6 MVC, twitch tension, time to peak tension, total 
contraction time, surface action potentials. 
7 n ? ? y ? ? y 2 H L n/a L H L H 
Koryak 1998(a)46 B&A 6 Maximal twitch response force, strength, MVC, 
Time-to peak tension, total contraction time. 
120 y ? ? y ? ? y 3 M L n/a L H L H 
Koryak 1998(b)47 RCT 4 MVC, evoked tetanic tension, maximal twitch 
tension, twitch time-to-peak tension, total contraction 
time. 
120 y ? ? y y ? y 4 M L n/a L H L H 
Koryak 199948 B&A 10 MVC, tension of maximal twitch, evoked tetanic 
tension, time to peak tension, total contraction time. 
120 y ? ? y y ? y 4 M L n/a L M L H 
Koryak 200249 B&A 6 Tension of maximal twitch, evoked tetanic tension, 
time to peak tension, total contraction time, surface 
action potential. 
7 n ? ? y y ? y 3 M L n/a L M L H 
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  Bed rest quality tool 
T
O
T
 
QUIPS risk of bias tool 
Study(analysis cross reference no.) Design n Outcomes Days  1 2 3 4 5 6 7 1 2 3 4 5 6 OVERALL  
Koryak 201050 RCT 6 MVC, twitch tension, time to peak tension, total 
contraction time. 
60 y y ? y y ? y 5 M L n/a L M L H 
Koryak 201451 RCT 6 Volume, electromyogram. 20 y ? ? y y ? y 4 M L n/a L M L H 
Kouzaki et al., 200752 RCT 6 Volume, electromyogram. 20 y ? ? y y ? y 4 M L n/a L M L H 
Krainski et al., 201453 RCT 9 Volume, torque. 35 y y y y y ? y 6 L L n/a L L L L 
LeBlanc et al., 198854 B&A 9 Cross-sectional area. 35 n y ? y y ? y 4 H L n/a L H L H 
Lee et al., 201455 RCT 24 Torque, 1RM, lean mass. 60 y y y y y ? y 6 L L n/a L L L L 
Macias et al., 200756 RCT 15 Strength, torque 28 y ? ? y y ? y 4 M L n/a L H L H 
Miokovic et al., 201157 RCT 9 Volume. 60 y y y y y ? y 6 M L n/a L M L H 
Miokovic et al., 201258 RCT 9 Volume. 60 y y y y y ? y 6 H L n/a L H L H 
Miokovic et al., 201459 RCT 8 Volume. 60 y y y y y ? y 6 H L n/a L H L H 
Muir et al., 201160 RCT 13 Strength, postural stability. 90 y ? y y y ? y 5 M H n/a L M L H 
Mulder et al., 200661 RCT 10 Cross-sectional area. 56 n y ? y ? ? y 3 L L n/a L H L H 
Mulder et al., 200762 RCT 10 Torque. 56 ? y ? y y ? y 4 L L n/a L M L H 
Mulder et al., 200863 RCT 8 Time to peak tension. 56 ? y ? y y ? y 4 L L n/a L M L H 
Mulder et al., 2009(a)64 RCT 9 Cross-sectional area, activity (EMG). 60 y y y y y ? y 6 H L n/a L H L H 
Mulder et al., 2009(b)65 RCT 10 Knee Extensor MVC. 56 N y ? y y ? y 4 L L n/a L M L H 
Narici et al., 199766 CS 8 Cross-sectional area, force. 17 y ? ? ? ? ? y 2 H L n/a M H L H 
Pisot et al., 200867 B&A 10 Contraction time, muscle maximal displacement 35 n y ? y y ? y 4 H L n/a L H L H 
Portero et al., 199668 B&A 12 MVC. 30 y ? ? y ? ? y 3 H L n/a L H L H 
Reeves et al., 200269 RCT 6 Force, resting fascicle length, fascicle length at mvc 90 y y ? y y ? y 5 M L n/a L M L H 
Rittweger et al., 200570 RCT 9 Cross-sectional area. 90 y y ? y ? ? y 4 L L n/a L H L H 
Rittweger et al., 201371 RCT 9 Cross-sectional area. 90 y y ? y ? ? y 4 M L n/a L M L H 
Schneider et al., 201672 RCT 8 Torque, work, lean mass. 30 y y ? y y ? y 5 H L n/a L L L H 
Shinohara et al., 200373 RCT 6 MVC, activity EMG  20 y y ? y y ? y 5 H L n/a L H L H 
Trappe et al., 200174 CS 8 Torque  17 y y ? ? ? ? y 3 H H n/a L H L H 
Trappe et al., 200775 RCT 8 Volume Force 60 y y ? y y y y 6 L L n/a L M L H 
Bedrest quality scores: 1 6 degrees head down tilt, 2 controlled diet, 3 fixed daily routine, 4 standardised bed rest phases, 5 uninterrupted bed rest, 6 restricted sunlight exposure, 7 
same outcome measures for all.  Quips risk of bias tool: 1 participation, 2, attrition, 3 prognostic factor measurement, 4 confounding factors, 5 statistical analysis and reporting. 
RCT: Randomised Controlled Trial.  CO: Cross over.  B&A: Before and after. TS: Time series.  CS: Cross sectional.  RCO: Randomised cross over 
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Table 3 Average effect sizes over time for muscle volumes 
 Days  
 7 14 20 27 28 29 35 42 55 56 57 89 90 
Plantar 
Fexor Muscles 
-0.3 
1.132 
-1.0 
1.011,12 
-0.4 
1.34,56 
-0.9 
1.058,59 
-1.8 
1.111,12 
-1.2 
1.05,75 
-1.7 
1.153 
-2.2 
1.211,12 
-1.3 
1.058,59 
-3.2 
1.411,12 
-2.6 
1.375 
-1.6 
1.15 
 
Dorsi Flexor 
Muscles 
 -0.4 
0.911, 12 
-0.1 
1.21,4,52 
-0.4 
1.058,59 
-0.5 
 0.911, 12 
 -0.5  
0.953 
-0.8  
1.011, 12 
-0.7  
1.058,59 
-2.8  
1.311, 12 
   
Quadriceps 
Muscles 
 -1.3 
 1.1211,12 
-0.5  
1.31,3,4 
-0.7  
158,59 
-1.7  
1.211,12 
-0.8  
15,75 
-0.6  
0.953 
-2.2  
1.3211,12 
-1.1  
1.17,58,59 
-2.8  
1.411,12 
-1.3 
1.175 
-1.4  
15 
 
Hamstring 
Muscles 
 -1.1  
1.111,12 
-0.5  
1.31,3,4 
-0.5  
158,59,57 
-1  
1.111,12 
  -1.8  
1.211,12 
-1.1  
158,59,57 
-2.2  
1.311,12 
   
Hip Adductor Muscles  -0.6  
1.111,12 
1.2 
 1.53,4 
-0.2  
158,59 
-0.7 
 1.111,12 
  -1.1 
 1.111,12 
-0.4  
158,59 
-1.1  
1.111,12 
   
Gluteal Muscles    -0.6  
157 
    -0.7  
157 
    
Hip Flexor Muscles             -0.3  
0.915 
OtherLower Limb Muscles -0.2 
1.232 
-0.7  
112 
-0.5 
1.31,3,4 
-0.8  
1.158,59,57 
-0.3 
 112 
  -0.6  
112 
-0.3 
 0.958,59,57 
-0.9  
1.112 
   
Erector Spinae Muscles    0.3  
0.917 
    0.3  
0.917 
   -0.5  
0.915 
Multifidus Muscle             -0.7  
115 
Other Trunk Muscles    0.4  
0.917 
    0.4  
0.917 
   -0.2  
0.915,41 
Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table
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Table 4 Average effect sizes over time for muscle cross sectional areas 
 Days 
 2 7 9 10 14 16 20 21 27 28 29 30 35 37 42 47 55 56 60 89 
Plantar Fexor Muscles -0.1 
1.229 
 -0.1 
1.229 
  -0.1 
1.229 
-0.3 
1.31,2 
-0.8 
1.123 
 -2.2 
1.270,71 
-0.2 
1.229 
-0.9 
1.021,25 
-0.6 
1.120,54 
     -1.8 
1.264 
-4.5 
1.870,71 
Dorsi Flexor Muscles       -0.2  
1.41 
    -1.3 
0.921 
-0.3 
0.954 
       
Quadriceps Muscles -0.1 
1.229 
 -0.1 
1.229 
 -0.7  
1.061 
-0.1  
1.229 
-0.4 
1.41 
-0.5  
1.123 
 -1.3 
 1.061 
-0.1 
1.229 
 -0.7  
1.320 
-1.1  
1.119 
-1.5  
1.161 
 -1.5  
1.064 
-1.9 
1.161,64 
  
Hamstring Muscles       -0.4 
 1.41 
             
Hip Adductor Muscles    -0.1  
0.943 
  -0.2 
 0.943 
             
Gluteal Muscles             -0.2  
1.220 
       
Hip Flexor Muscles        0.2 
1.116 
0.0  
0.913,14 
       0.0  
0.913,14 
 -0.2  
1.042 
 
Other Lower Limb Muscles       -0.6 
 1.41 
    -1.2  
1.225,21 
   -1.0  
1.133 
    
Erector Spinae Muscles        0.6  
1.116 
0.8  
1.013,14 
       -1.0  
1.013,14 
-1.1  
0.910 
-1.1  
1.042 
 
Multifidus Muscle  -0.4  
1.018 
  -0.4  
1.018 
  -0.5  
1.116 
-0.5 
0.913,14 
-0.6 
1.018 
    -0.3  
1.018 
 -0.7  
1.013,14 
-0.7  
1.418,10 
-1.1  
1.142 
 
Other Trunk Muscle        -0.1  
1.016 
-0.3  
0.913,14 
       -0.4 
0.913,14 
 -1.0 
1.142 
 
Upper Limb Muscles          -0.9 
1.070,71 
         -1.4 
1.170,71 
Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table 
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Table 5 Average effect sizes over time for torques and strength 
 Days 
 4 7 10 14 17 20 21 24 26 28 30 38 42 55 56 60 90 
Plantar Fexor Muscles    -0.3 
1.031,8 
0.1 
1.074 
-0.4 
1.12 
-0.2 
1.123 
  -0.4 
1.072 
-0.7 
0.868 
  -1.7 
1.164 
 -1.7 
0.755 
-2.0 
1.15,60 
Dorsi Flexor Muscles          -0.3 
1.072 
-0.6 
0.868 
    -0.9 
0.655 
-0.3 
0.860 
Quadriceps Muscles -0.2 
0.965 
-0.3 
0.965 
-0.3 
0.965 
-0.8 
1.031 
-0.4 
0.965 
-0.7 
1.41 
-0.3 
0.723 
-0.6 
0.965 
 -0.5 
1.137,72 
-0.6 
1.127 
-0.9 
0.965 
-2.2 
1.319 
-2.0 
1.164 
-1.0 
0.962,65 
-1.7 
1.1255,31 
-3.2 
1.45,60,6 
Hamstring Muscles 0.0 
0.961 
-0.1 
0.961 
0.0 
0.961 
 -0.1 
0.961 
  -0.4 
0.961 
 -0.4 
1.072 
-0.2 
1.127 
-0.7 
1.061 
  -0.8 
1.061 
-1.7 
0.755 
-0.5 
0.860 
Hip Extensor Muscles            -0.1 
0.953 
     
Hip Flexor Muscles            -0.1 
0.953 
     
Other Trunk                -2.2 
1.542,30 
-0.5 
0.915,60 
Upper Limb Muscles   -0.1 
1.239 
     0.1 
1.239 
 -0.4 
0.756 
-0.1 
0.953 
     
Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table
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Table 6 Average effect sizes over time for contractile work capacity 
 Days 
 14 
Plantar Flexors -0.6 
1.08 
Quadricpes -0.6 
0.931 
Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table 
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Table 7 Average effect sizes over time for muscle thickness 
 Days 
 7 14 26 35 42 56 
Plantar Fexor Muscles    -1.4 
1.026 
  
Dorsi Flexor Muscles    -0.9 
0.926 
  
Quadriceps Muscles    -1.8 
1.026 
  
Erector Spinae Muscles -0.5 
1.018 
-0.5 
1.018 
-0.5 
1.018 
 -0.5 
1.018 
-0.5 
1.018 
Internal Oblique Muscle  -0.9 
1.018 
-0.9 
1.018 
 -0.8 
1.018 
-0.8 
1.018 
Transversus Abdominis Muscle  -1.6 
1.118 
-1.4 
1.118 
 -1.4 
1.118 
-1.4 
1.118 
Upper Limb 
Muscles 
   0.9 
0.926 
  
Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table 
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Table 8 Average effect sizes over time for peak power 
 Days 
 56 60 62 90 
Plantar Fexor Muscles   -1.6 
1.175 
-2.1 
1.25 
Quadriceps 
Muscles 
  -1.4 
1.175 
-1.9 
1.15 
Jump -1.6 
1.022 
-2.3 
1.26 
  
Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table 
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Table 9 Average effect sizes over time for EMG muscle activity 
 Days 
 14 15 20 21 30 45 55 56 90 
Plantar 
Fexor 
Muscles 
0.0 
1.08 
 0.4 
1.252,73 
-0.2 
1.064 
  -0.2 
1.064 
0.2 
0.922 
-0.9 
1.05 
Dorsi Flexor 
Muscles 
-0.5 
1.28,24 
 0.5 
1.152 
      
Quadriceps 
Muscles 
-0.5 
1.424 
 0.3 
1.23,73 
-0.1 
0.964 
  -0.1 
0.964 
 -0.9 
1.05 
Erector Spinae Muscles    -0.3 
1.116 
     
Mutifidus 
Muscle 
   -0.2 
1.116 
     
Hip Flexor 
Muscles 
   -0.2 
1.116 
     
Shoulder 
Muscles 
 -0.6 
1.034 
  -0.5 
1.034 
-0.3 
1.034 
   
Forearm 
Muscles 
 -0.7 
1.034 
  -0.8 
1.034 
-0.6 
1.034 
   
Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table 
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Table 10 Average effect sizes over time for MVC during one rep max 
  Days    
 6 7 10 13 14 15 17 20 26 28 30 35 45 56 60 62 90 120 
Plantar Fexor Muscles  -0.7 
1.245,49 
  -1.1 
1.18 
 -0.3 
1.066 
-0.4 
1.173 
     -0.8 
0.922 
-1.4 
1.350 
-2.1 
1.375 
-1.7 
1.169,75 
-2.0 
1.544,46,47,48,51 
Dorsi Flexor Muscles     -0.1 
1.08 
         -0.5 
0.655 
   
Quadriceps Muscles  -0.5 
1.335 
  -0.7 
1.335 
  -0.8 
1.33,35,73 
 -0.3 
1.072 
 -1.4 
1.420 
  -1.1 
0.655 
-1.5 
1.175,36 
-2.4 
1.25 
 
Hamstring Muscles  -0.4 
1.335 
  -0.8 
1.335 
  -1.1 
1.335 
 -0.6 
1.072 
        
Hip Flexor Muscle  -0.9 
1.335 
  -1.0 
1.335 
  -1.0 
1.335 
          
Other lower limb -0.3 
1.239 
  -0.6 
1.339 
   -0.6 
1.339 
 -0.5 
1.339 
 -0.9 
1.320 
    -1.5 
1.06 
 
Other upper limb  0.0 
1.235 
0.2 
1.239 
 -0.1 
1.235 
-0.2 
1.034 
 -0.5 
1.335 
-0.1 
1.239 
 -0.0 
1.034 
-0.0 
1.220 
-0.0 
1.034 
     
Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table
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Table 11 Average effect sizes over time for power 
 Days 
 7 14 20 
Plantar Fexor Muscles  -0.5 
1.08 
 
Quadricep Muscles -0.6 
1.335 
-0.9 
1.335 
-1.7 
1.535 
Hamstring Muscles -0.1 
1.235 
-0.4 
1.235 
-0.6 
1.335 
Hip Flexor Muscles -0.3 
1.235 
-0.5 
1.335 
-0.6 
1.335 
Other upper limb -0.0 
1.235 
-0.2 
1.235 
-0.6 
1.335 
Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table 
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Table 12 Average effect sizes over time for performance based 
 Days 
 14 30 42 44 56 60 62 90 
Endurance -1.1 
1.138 
-1.2 
0.968 
      
Jumping   -0.6 
1.119 
-2.0 
1.333 
-1.2 
1.022 
-2.3 
1.336 
  
Sit to stand      -1.1 
1.036 
  
Balance      1.2 
0.860 
 1.1 
0.860 
Sprint time       2.1 
1.136 
 
Bold is effect size, underneath is 95% confidence interval with superscript cross reference to study ID in characteristics of analysed studies table 
 
 
